Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
Phillip Low, PhD
Advertisement
Articles by Phillip Low, PhD
CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
